Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009631 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT02009631 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 45 participants.
The verdict
NCT02009631, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.
Interventions
- DRUG Placebo
- DRUG Veliparib (ABT-888)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009631
The ClinicalTrials.gov registry entry for NCT02009631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02009631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009631 about?
NCT02009631 is a clinical study titled "A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors". This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.
What is the current status of trial NCT02009631?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2013-11. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02009631?
The interventions under investigation include: Placebo (DRUG), Veliparib (ABT-888) (DRUG).
Who is sponsoring clinical trial NCT02009631?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.